IL6 and diffuse large B-cell lymphoma: Although bone marrow infiltration is not common in DLBCL, the studies of this milieu in the context of therapy efficacy need to be developed as bone marrow-derived MSCs have been shown to promote the growth and primary resistance of DLBCL cell lines to rituximab by secreting IL-6 and elevating IL-17A levels in in vitro settings [143].